Therapeutic indications

Amifampridine is indicated for:

Lambert-Eaton myasthenic syndrome (LEMS)

Irrespective of gender only Adults (18 years old or older)

Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 15-60 mg in 3 divided doses daily


Active ingredient Amifampridine is contraindicated in the following cases:

Medicinal products that can prolong QTc interval

Based on the pharmacodynamic properties of amifampridine, the concomitant use with medicinal products known to cause QT prolongation (e.g., disopyramide, cisapride, domperidone, rifampicin and ketoconazole) is contraindicated as this combination may lead to an enhanced risk of ventricular tachycardia, notably torsade de pointes.

Medicinal products with a narrow therapeutic window


Concomitant use with sultopride.

Uncontrolled asthma

Congenital QT syndrome

In patients with congenital QT syndromes.


Medication Recommendation

Receive personalized medication regimen for every patient case

Ask the Reasoner

Related medicines